Kythera: This aesthetic medicine company is probably the most interesting IPO of the group from a venture perspective.

FORBES: Biotech IPOs Are Back! Maybe.

Two recent offerings, Kythera and Intercept, both ripped out of the gates with 20% rallies above their offer price last week.

FORBES: Biotech IPOs Are Back! Maybe.

Those companies are Shutterstock, Realogy, Intercept Pharmaceuticals and Kythera Biopharmaceuticals.

FORBES: IPO Watch: Workday, Real Estate And Double Chins

Kythera trades on the Nasdaq under the ticker KYTH.

FORBES: IPO Watch: Workday, Real Estate And Double Chins

To better understand the relative attractiveness of the IPO market, and how their venture backers have done so far, I thought it would be illustrative to look at the biotech IPOs that have made it public since early July in greater depth: Durata, Hyperion, Regulus, Kythera, and Intercept.

FORBES: Biotech IPOs Are Back! Maybe.